SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Sharck Soup -- Ignore unavailable to you. Want to Upgrade?

To: velociraptor_ who wrote (22337)5/11/2001 10:19:47 AM
From: Sharck  Respond to of 37746
 
QLTI thanks V, I think this is the news I was looking for:
This was on DJ Hot Stocks this am....QLTI...will need to perform a second trial of Visudyne before it can expand the label of its flagship drug to the occult from of AMD...Also, RBC Dominion cuts Qlti target to C$44 from C$50



To: velociraptor_ who wrote (22337)5/11/2001 10:37:21 AM
From: Jim Spitz  Respond to of 37746
 
Visudyne sounds promising. My mom has AMD as does her older sister. She found that bilberry(sp?) helps some, but this treatment could provide more benefit. I'm printing the report for her Eye Doctor.

Stay in the Black! jimS


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News